Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
NCT01267227Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Countries
- 1
- Sponsor
- University of Mississippi Medical Center
- Modality
- Small Molecules
- Drugs
- pTeroPure
- Conditions
- hyperlipidemiahypertension (HTN)
01
Overview
Phase 3, randomised, double-blind trial of pTeroPure in hyperlipidemia and hypertension (HTN) (4 arms), sponsored by University of Mississippi Medical Center. Primary endpoint: Low Density Lipoprotein. Started Dec 2010; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
High Dose
Pterostilbene 125 mg twice daily
Low Dose
Pterostilbene 50 mg twice daily
Low Dose Combination
Pterostilbene 50 mg + Grape Extract 100 mg twice daily
Placebo
Matching placebo twice daily
03
Endpoints
Primary
Low Density Lipoprotein
Secondary
Blood Pressure
Subjective Adverse Effects
Beyond the preview
Go deeper on NCT01267227.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267227.